{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=74", "query": { "intervention": "combined treatment", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 13990, "total_pages": 1399, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=75&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=73&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T16:47:42.323Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05023486", "title": "NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumor Malignancies" ], "interventions": [ { "name": "NP-G2-044 Monotherapy", "type": "DRUG" }, { "name": "Anti-PD-1 Therapy", "type": "DRUG" }, { "name": "NP-G2-044 Combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novita Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2021-12-07", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05023486" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT00003402", "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "1999-01", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003402" }, { "nct_id": "NCT03019003", "title": "Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Oral Decitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "5' Azacitidine", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-03-20", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019003" }, { "nct_id": "NCT01396486", "title": "Inositol and Omega-3 Fatty Acids in Pediatric Mania", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pediatric Bipolar Spectrum Disorders" ], "interventions": [ { "name": "Omega-3", "type": "DRUG" }, { "name": "Inositol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "5 Years to 12 Years" }, "enrollment_count": 69, "start_date": "2012-02-03", "completion_date": "2019-04-11", "has_results": true, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396486" }, { "nct_id": "NCT01326286", "title": "Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "MALE", "summary": "18 Years to 79 Years · Male only" }, "enrollment_count": 3265, "start_date": "2011-03", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01326286" }, { "nct_id": "NCT05005273", "title": "A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "BMS-986207", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-10-03", "completion_date": "2022-12-27", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 17, "location_summary": "Tucson, Arizona • Fountain Valley, California • Fort Myers, Florida + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005273" }, { "nct_id": "NCT02758756", "title": "Pilot Study on Energy Therapy or Massage to Reduce Fatigue", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fatigue" ], "interventions": [ { "name": "Massage", "type": "OTHER" }, { "name": "Reiki", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 87, "start_date": "2016-06-20", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758756" }, { "nct_id": "NCT04038502", "title": "Carboplatin or Olaparib for BRcA Deficient Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castrate Resistant Prostate Cancer", "BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2", "RAD51B, RAD51C, RAD51D, or RAD54L Mutations" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2019-10-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 18, "location_summary": "West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "West Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04038502" }, { "nct_id": "NCT05860296", "title": "Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer, Nonsmall Cell", "Lung Cancer Stage IV", "Lung Cancer Metastatic" ], "interventions": [ { "name": "SLC-391", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SignalChem Lifesciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-05-31", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-11-01T16:47:42.323Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05860296" } ] }